Stock Price, News, Quote and Profile of EVAXION BIOTECH A/S(NASDAQ:EVAX) stock

EVAXION BIOTECH A/S

NASDAQ:EVAX (12/27/2024, 8:16:55 PM)

After market: 1.08 +0.02 (+1.89%)

1.06

+0.21 (+25.3%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%98.1%

Sales Q2Q%N/A

CRS0.97

6 Month-63.45%

Overview

Earnings (Last)10-31 2024-10-31/bmo

Earnings (Next)N/A N/A

Ins Owners0.68%

Inst Owners8.19%

Market Cap6.22M

Shares5.87M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts84.44

Short Float %0.75%

Short Ratio0.62

IPO02-05 2021-02-05

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Company Info

EVAXION BIOTECH A/S

Bredgade 34E, Copenhagen K

COPENHAGEN 1260

CEO: Lars Staal Webner

Employees: 49

Website: https://www.evaxion-biotech.com/

EVAX News

2 days ago - ChartmillWhich stocks are moving after the closing bell on Thursday?

These stocks are moving in today's after hours session

2 months ago - Evaxion BiotechEvaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

New preclinical data demonstrates that CMV antigens identified with Evaxion’s AI-Immunology™ platform trigger targeted immune responses Results also...

2 months ago - Evaxion BiotechEvaxion announces business update and third quarter 2024 financial results

COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing...

2 months ago - Evaxion BiotechEvaxion to announce business update and third quarter 2024 financial results on October 31

COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing...

3 months ago - Evaxion BiotechStrong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials

Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets...

EVAXION BIOTECH A/S (EVAX)

Nasdaq Stock Screener

USA Stock Screener